Full-Dose Anticoagulation Cuts VTE in Severe COVID-19
(MedPage Today) -- BARCELONA -- Full-dose anticoagulation prevented thromboembolic events in critically ill COVID-19 patients in the COVID-PACT trial. However, modest antithrombotic doses and colchicine didn't pan out in or out of the hospital... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 31, 2022 Category: Cardiology Source Type: news
Benemid (Probenecid and Colchicine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 25, 2022 Category: Drugs & Pharmacology Source Type: news
Platform trial rules out treatments for COVID-19, NIHR Evidence
This research shows that adding doxycycline, azithromycin or colchicine to usual care provides no meaningful benefit to people in the community with COVID-19. They should not be used. Antibiotics should always be used sparingly to prevent bacteria becoming resistant to them. Use of any drug which is not effective puts people at unnecessary risk of side effects, and wastes money. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 18, 2022 Category: Consumer Health News Source Type: news
WHO Guideline Advises Against Fluvoxamine, Colchicine for COVID-19
FRIDAY, July 15, 2022 -- Fluvoxamine and colchicine are not recommended for nonsevere COVID-19, according to the 11th version of the World Health Organization living guideline on drugs for COVID-19 published online July 13 in The BMJ.
Arnav Agarwal,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 15, 2022 Category: Pharmaceuticals Source Type: news
Don't Use Luvox, Colchicine to Fight COVID, WHO Experts Say
FRIDAY, July 15, 2022 -- People shouldn ’t take the drugs colchicine and fluvoxamine to treat mild to moderate COVID-19, the World Health Organization (WHO) is warning.
The antidepressant drug fluvoxamine (Luvox) and the gout drug colchicine are... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 15, 2022 Category: General Medicine Source Type: news
Update to living WHO guideline on drugs for covid-19, BMJ (Published 13th July 2022)
Latest version provides two new recommendations for patients with non-severe covid-19: a recommendation against use of fluvoxamine except in the context of a clinical trial and a strong recommendation against use of colchicine. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 15, 2022 Category: Consumer Health News Source Type: news
WHO Experts Advise Against a Generic Antidepressant to Treat COVID-19
A generic antidepressant and a gout medicine that garnered some popularity as COVID-19 treatments shouldn’t be used for mild infection because there’s no evidence they help, according to a panel of experts advising the World Health Organization.
The drugs, fluvoxamine and colchicine, could potentially cause harm, the group of experts said in the BMJ medical journal Thursday. The panel didn’t give advice for severe illness, saying there was a lack of data.
The two medicines “are commonly used, inexpensive drugs that have received considerable interest as potential COVID-19 treatments during the pande...
Source: TIME: Health - July 14, 2022 Category: Consumer Health News Authors: Marthe Fourcade / AP Tags: Uncategorized COVID-19 healthscienceclimate wire Source Type: news
NIHR Alert: Platform trial rules out treatments for COVID-19, NIHR
Expert commentary is provided for a trial which found adding doxycycline, azithromycin or colchicine to usual care provides no benefit to people in the community with COVID-19. These data are useful as preventing ineffective antibiotic use is critical to reduce drug resistance. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 6, 2022 Category: Consumer Health News Source Type: news
Multidirectional analysis for a colchicine poisoning case revealed detail cause of death and its mechanism - Okuda K, Isozaki S, Asari M, Tanaka H, Horioka K, Takahashi Y, Hoshina C, Yamada H, Mori K, Namba R, Shiono H, Ogawa K, Shimizu K.
The appearance of Meadow saffron (Colchicum autumnale), which contains colchicine, closely resembles Alpine leek (Allium victorialis), a popular edible wild vegetable in Northern Japan. This often results in the accidental ingestion of Meadow saffron and a... (Source: SafetyLit)
Source: SafetyLit - June 6, 2022 Category: International Medicine & Public Health Tags: Home and Consumer Product Safety Source Type: news
Gout Drug May Cut Mortality in Heart Failure Hospitalizations
WEDNESDAY, May 25, 2022 -- Among patients with an acute heart failure exacerbation, treatment with colchicine for a gout flare is associated with significantly lower in-hospital mortality, according to a study published online April 28 in Clinical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 25, 2022 Category: Pharmaceuticals Source Type: news
Gout Medicine Colchicine May Also Help Fight Heart Failure
MONDAY, May 23, 2022 -- The anti-inflammatory benefits of a common gout medicine may help save the lives of heart failure patients, researchers say.
The medication, colchicine, could also reduce the risk of heart attack and stroke in patients whose... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 23, 2022 Category: General Medicine Source Type: news
A fatal colchicine ingestion with antemortem blood concentration - McCabe DJ, Wilson BZ, Radke JB, Bottei EM.
Although there are multiple therapeutic uses for colchicine, it is particularly dangerous in the setting of overdose due to an irreversible mechanism of action combined with a narrow therapeutic window. Colchicine is an antimitotic agent that binds tubulin... (Source: SafetyLit)
Source: SafetyLit - April 4, 2022 Category: International Medicine & Public Health Tags: Poisoning Source Type: news
Coronavirus (COVID-19): evidence relevant to acute and critical care, Cochrane Library (updated 22nd March 2022)
Updated 22 March 2022 to expand the title and scope of the collection from ' evidence relevant to critical care ' to ' evidence relevant to acute and critical care ' ; to add two Cochrane Clinical Answers to the review ' Colchicine for the treatment of COVID-19 ' ; and to add the new review ' Inhaled corticosteroids for the treatment of COVID-19 ' and its associated Cochrane Clinical Answer. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 31, 2022 Category: Consumer Health News Source Type: news
Palliative Care in Assisted Living
Mrs. M is a 92-year-old woman residing in an assisted living community. Her medical history includes hypertension, gout, hyperlipidemia, atrial fibrillation, hypothyroidism, and melanoma with invasion into the parotid gland; she has had removal of a lesion and a parotidectomy with nerve involvement impacting the 7th cranial nerve. Her medications include oral levothyroxine, 100 μg daily; oral vitamin D, 1,000 units daily; oral probenecid 500/colchicine, 0.5 mg daily; oral lisinopril, 5 mg daily; oral furosemide, 20 mg daily; oral duloxetine, 60 mg for depression; oral carvedilol, 6.25 mg twice a day; oral aspirin, 81 mg d...
Source: Caring for the Ages - March 29, 2022 Category: Health Management Authors: Barbara Resnick, Paige Hector Tags: Interdisciplinary Team Case Studies Source Type: news
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial, BJGP
Primary analysis model (n=2755) found colchicine did not improve time to recovery vs. usual care in people at higher risk of complications with COVID-19 in the community (HR 0.919;95% CI 0.72-1.16), with~increase of 1.4 days in median time to self-reported recovery for colchicine (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 25, 2022 Category: Consumer Health News Source Type: news
